Shares of Small-cap health care company CorMedix moved 16.8% this afternoon, and are now trading at $5.18 per share. The average analyst target price for the stock is $16.67.
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.
Based on its trailing earning per share of -0.63, CorMedix has a trailing 12 month Price to Earnings (P/E) ratio of -8.2 CRMD has a forward P/E ratio of -5.8 based on its earnings guidance of None.
CRMD Has an Exceptionally Strong Balance Sheet
| 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| Revenue (k) | $283 | $239 | $191 | $65 |
| Operating Margins | -7416.3% | -11378.4% | -15417.5% | -46819.9% |
| Net Margins | -5801.29% | -9207.7% | -14774.7% | -45409.9% |
| Net Income (k) | -$16,433 | -$22,028 | -$28,210 | -$29,702 |
| Net Interest Income | -$465 | $83 | -$2 | $300 |
| Depreciation & Amort. | -$73 | -$128 | -$62 | -$85 |
| Earnings Per Share | -$1.8 | -$0.77 | -$0.75 | -$0.63 |
| EPS Growth | n/a | 57.22% | 2.6% | 16.0% |
| Diluted Shares (k) | 24,152 | 28,562 | 37,666 | 41,282 |
| Free Cash Flow (k) | -$15,052 | -$21,968 | -$21,155 | -$24,357 |
| Capital Expenditures | -$37 | -$113 | -$1,425 | -$219 |
| Net Current Assets (k) | $23,519 | $43,097 | $60,321 | $52,573 |
| Current Ratio | 5.04 | 11.58 | 12.44 | 9.44 |
